Botulinum neurotoxin versus tizanidine in upper limb spasticity: A placebo-controlled study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 4, 2009, Pages 380-385

  Simpson, D M ^a,f   Gracies, J M ^a,b   Yablon, S A ^c   Barbano, R ^d   Brashear, A ^e   Team, T B S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; LIVER ENZYME; PLACEBO; TIZANIDINE; BOTULINUM TOXIN; CENTRAL MUSCLE RELAXANT; CLONIDINE; DRUG DERIVATIVE; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARM DISEASE; ARM MUSCLE; ARM SPASTICITY; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY ASSESSMENT SCALE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; ELBOW; FALLING; FATIGUE; FEMALE; FINGER; FLEXOR MUSCLE; HEADACHE; HUMAN; INCIDENCE; MALE; MODIFIED ASHWORTH SCORE; MULTICENTER STUDY; MUSCLE TONE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STOMACH PAIN; STROKE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; ADOLESCENT; ARM; MIDDLE AGED; PHYSIOLOGY; WRIST;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS; CLONIDINE; DOUBLE-BLIND METHOD; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME; UPPER EXTREMITY; WRIST; YOUNG ADULT;

EID: 64749110674     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.159657     Document Type: Article

References (23)

1. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Circulation 2006;113:85-151e.
2. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
3. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve 2005;31:552-71.
4. Gracies JM, Elovic E, McGuire J, et al. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl 1997;6:61-91S.
5. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006;29:31-48.
6. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebocontrolled trial. Neurology 1996;46:1306-10.
7. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebocontrolled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6.
8. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506.
9. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-12.
10. Smith SJ, Ellis E, White S, et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
11. Childers M. Myofascial pain syndromes. In: Botulinum toxin type A in pain management. 2nd ed. Columbia, MO: Academic Information Systems, 2002:77-100.
12. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300.
13. VanDenbergh A, Abu-Shakra S, Brin M, et al. Passive and active functional tasks are the main reasons for treatment of upper limb spasticity in poststroke patients among neurologists, physiatrists, and primary care physicians [abstract]. Arch Phys Med Rehab 2007;88:E104.
14. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
15. Gracies JM, Weisz DJ, Yang BY, et al. Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Arch Phys Med Rehab. In press.
16. Chin TY, Nattrass GR, Selber P, et al. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 2005;25:286-91.
17. Gracies JM, Hefter H, Simpson D, et al. Botulinum toxin in spasticity. In: Moore P, Naumann M, ed. Handbook of botulinum toxin. 2nd edn. Oxford: Blackwell Science, 2002:221-74.
18. Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group [discussion 51-2S]. Neurology 1994;44:44-51S.
19. Mathias CJ, Luckitt J, Desai P, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev 1989;26:9-16.
20. Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32:1841-6.
21. Montane E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004;63:1357-63.
22. Brans JWM, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial. Neurology 1996;46:1066-72.
23. Adler CH, Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology 2000;55:9-14S.